BeyondBio Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 23

Employees

  • Latest Deal Type
  • Series E

  • Investors
  • 8

BeyondBio General Information

Description

Developer of therapeutic drugs intended to offer drugs that will protect human beings from life-threatening diseases. The company develops drug candidates and therapies for diseases that do not have available treatment such as pancreatic cancer, Alzheimer's, and glioblastoma, enabling medical practitioners to protect people from life-threatening diseases.

Contact Information

Website
www.beyondbio.co.kr
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 42, Gukjegwahak 13-ro
  • Yuseong
  • Daejeon, 34002
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 42, Gukjegwahak 13-ro
  • Yuseong
  • Daejeon, 34002
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BeyondBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series E) 12-Jun-2026 Completed Clinical Trials - Phase 1
5. Secondary Transaction - Private Completed Clinical Trials - Phase 1
4. Later Stage VC (Series D) 21-Sep-2021 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series C) 01-Apr-2018 Completed Pre-Clinical Trials
2. Early Stage VC (Series B) 01-Jun-2016 Completed Startup
1. Early Stage VC (Series A) 01-Jun-2014 Completed Startup
To view BeyondBio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

BeyondBio Patents

  • 25

    Total Documents Applications and Grants

  • Total Patents Families

  • 17

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

BeyondBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2021045582-A1 2,6-bis-(2-aminopyrimidin-4-yl)pyridin-3-ol dihydrochloride and pharmaceutical composition comprising same Inactive 06-Sep-2019
WO-2021045586-A1 2'-amino-6-(2-amino-6-(1-isopropylpiperidin-4-yl)-5-methylpyrimidin-4-yl)-3'-fluoro-[2,4'-bipyridine]-5-ol 3-hydrochloride and pharmaceutical composition comprising same Inactive 06-Sep-2019
WO-2021045584-A1 2'-amino-6-(2-amino-6-methylpyrimidine-4-yl)-3'-fluoro-[2,4'-bipyridine]-5-ol dihydrochloride and pharmaceutical composition comprising same Inactive 06-Sep-2019
EP-4029861-A1 Method for producing pyrimidinyl bipyridine compound and intermediate therefor Active 06-Sep-2019
EP-4029861-A4 Method for producing pyrimidinyl bipyridine compound and intermediate therefor Active 06-Sep-2019 A61P35/00
To view BeyondBio’s complete patent history, request access »

BeyondBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BeyondBio Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
JX Partners Venture Capital Minority
K-Clavis Asset Manager Minority
Tiger Asset Management Hedge Fund Minority
Woori Venture Partners Venture Capital Minority
DT & Investment Corporate Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

BeyondBio FAQs

  • When was BeyondBio founded?

    BeyondBio was founded in 2013.

  • Where is BeyondBio headquartered?

    BeyondBio is headquartered in Daejeon, South Korea.

  • What is the size of BeyondBio?

    BeyondBio has 23 total employees.

  • What industry is BeyondBio in?

    BeyondBio’s primary industry is Drug Discovery.

  • Is BeyondBio a private or public company?

    BeyondBio is a Private company.

  • What is BeyondBio’s current revenue?

    The current revenue for BeyondBio is .

  • How much funding has BeyondBio raised over time?

    BeyondBio has raised $14.5M.

  • Who are BeyondBio’s investors?

    JX Partners, K-Clavis, Tiger Asset Management, Woori Venture Partners, and DT & Investment are 5 of 8 investors who have invested in BeyondBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process